Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression

Dr. Lan Coffman presents updated Phase III MIRASOL trial results comparing overall survival and safety outcomes of mirvetuximab soravtansine (MIRV) versus investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer and high folate receptor-alpha expression.

Read the full article here

Source: www.onclive.com

Categories: Oncologists1, General Medicine News

Tags: OvarianCancer

Tweets with this article

OncLive.com

Lan Coffman, MD, PhD, of @UPMCHillmanCC presents updated results from the Phase III MIRASOL trial comparing mirvetuximab soravtansine vs investigator’s choice chemotherapy in platinum-resistant #ovariancancer. Watch more here: https://t.co/7RBq3AqYrV https://t.co/j51YwlzePO

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.

OncLive.com December 21, 2024

Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study | JCO Global Oncology

PURPOSETrimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM),…

Enrique Soto December 21, 2024

Related Articles